Subsequent studies have shown that this phenomenon could be linked to a slowing of gastric emptying by GLP-1, as well as by the action of this hormone at the level of certain neural circuits of the brain involved in the suppression of appetite and the development of nausea
The results reported a 6.0%, 6.8%, 9.1%, 9.7%, and 10.8% decrease in body weight for the groups receiving cagrilintide in doses of 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, and 4.5 mg, respectively [1]
PDZK1 directly regulates the function of organic cation/carnitine transporter OCTN2
Support Your Energy and Weight Goals
Can GLP-1s be used for non-alcoholic fatty liver disease
Dose reduction remains the most reliable solution if water retention becomes genuinely bothersome